Answers are grounded in this paper and cite their sources.
GSK-3β is a key regulator in insulin, Wnt and NF-κB signaling pathways. Dysregulation of GSK-3β is often related to tumors and diabetes. Inhibiting it might provide cure for diabetes, tumors, neurodegeneration and brain ischemia. Although there are a number of reported GSK-3β inhibitors, the scaffold is limited. Herein we report a discriminatory analysis-based molecular docking on the Specs database, and identified 3 novel GSK-3β inhibitors with moderate IC50 (ranging from 17.42 μM to 6.74 μM) in the following in vitro biological test. Further dynamic simulations and docking pose analysis were performed to give a better understanding on the binding conformation of 3 hit compounds AK- 777/09836064, AK-968/37185006 and AN-698/41607072, which would provide basis for further optimization.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2021) studied this question.
Synapse has enriched 9 related papers. Consider them for comparative context: